More relevant: they also help pharma sponsors who "cannot demonstrate the clinical benefit statistically". And: "Often, companies come to us looking for solutions with their clinical trials that have issues. For example, the company could be in phase II and looking to meet their end point, in these types of cases we are able to assist our clients."
Etc, etc. The company is likely sharpening its pencil with the incoming Phase 2A Part B results, to get to signal; we have a small-n trial with high variation to baseline and potential stratification. Looking forward to the 36-week release.
News 
Market Data 
Discover 
AI
